PDCD1 and cancer: In both cancer and chronic viral infection, a subset of T cells expressing high levels of PD-1 (Pdcd1) and other inhibitory checkpoints proliferates and differentiates into effectors that can mediate long-term immune control after anti-PD-1 immunotherapy50,51.